Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)
 
 • Company Description   
Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States.

Number of Employees: 87

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.63 Daily Weekly Monthly
20 Day Moving Average: 196,412 shares
Shares Outstanding: 37.87 (millions)
Market Capitalization: $516.11 (millions)
Beta: 0.45
52 Week High: $19.77
52 Week Low: $7.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 8.52% 4.80%
12 Week 33.11% 12.33%
Year To Date 4.13% -2.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
16305 36TH AVENUE NORTH SUITE 100
-
MINNEAPOLIS,MN 55446
USA
ph: 763-392-0767
fax: -
None http://www.celcuity.com
 
 • General Corporate Information   
Officers
Brian F. Sullivan - Chief Executive Officer and Chairman
Vicky Hahne - Chief Financial Officer
Lance G. Laing - Vice President and Secretary and Director
Richard E. Buller - Director
Dave F. Dalvey - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 15102K100
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 37.87
Most Recent Split Date: (:1)
Beta: 0.45
Market Capitalization: $516.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.94 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.95
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -34.38%
vs. Previous Quarter: -1.18%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -96.21
12/31/24 - -77.66
ROA
06/30/25 - -
03/31/25 - -49.44
12/31/24 - -44.76
Current Ratio
06/30/25 - -
03/31/25 - 6.61
12/31/24 - 7.71
Quick Ratio
06/30/25 - -
03/31/25 - 6.61
12/31/24 - 7.71
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.29
12/31/24 - 3.11
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.14
12/31/24 - 0.85
Debt-to-Capital
06/30/25 - -
03/31/25 - 53.20
12/31/24 - 45.81
 

Powered by Zacks Investment Research ©